Table 2.
Unadjusted (n = 584) | Model 1* (n = 583) | Model 2† (n = 528) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Baseline A1C | N | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value |
6.5–8.0% | 162 | 1.00 | Ref | — | 1.00 | Ref | — | 1.00 | Ref | — |
<6.5% | 149 | 1.00 | 0.69–1.47 | 0.96 | 0.99 | 0.69–1.43 | 0.96 | 0.97 | 0.65–1.44 | 0.89 |
>8.0% | 298 | 1.18 | 0.89–1.58 | 0.26 | 1.13 | 0.83–1.54 | 0.44 | 0.97 | 0.70–1.36 | 0.87 |
N, number of wounds.
P values <0.05 are statistically significant.
*Model 1 adjusted for age, sex, and race; one observation was dropped due to missing race.
†Model 2 adjusted for age, sex, race, smoking status, neuropathy (LOPS), prior amputation, quartiles of insulin dose (units/kg/day), metformin use, sulfonylurea use, wound intervention (surgery vs. wound care only), eGFR category, kidney transplant, A1C target (<7.5% vs. ≥7.5%), and antibiotic use; 56 observations were dropped from model 2: 54 missing eGFR, 1 missing race, and 1 missing insulin dose.